RxDoctor Payments Data

Christopher Miller, MD

Internal Medicine · Dothan, ALNPI 1477528990

Payments from drug & device makers

$13,829in general payments, 2019–2025

Across 869 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Amgen$1K
  • Novo Nordisk$1K
  • AbbVie$950
  • AstraZeneca$847
  • Johnson & Johnson$673
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,809100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK63$1,194
Amgen84$1,101
Novo Nordisk72$1,033
AbbVie(2 entities)55$950
AstraZeneca50$847
Johnson & Johnson54$673
Gilead36$611
Novartis44$591
Lilly USA, LLC47$548
Merck44$545
Smith+Nephew31$537
Pfizer41$535
Bayer25$502
Amarin Pharma, Inc.29$469
Abbott22$363
Boehringer Ingelheim26$318
Phathom Pharmaceuticals, Inc.5$295
Kerecis Limited4$216
E.r. Squibb & Sons, L.L.C.12$171
Esperion Therapeutics, Inc.8$165
Averitas Pharma Inc.6$165
Eisai Inc.10$162
Organogenesis Inc.9$152
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$123
Dexcom, Inc.7$111
Solventum Corporation3$111
Biohaven Pharmaceutical Holding Company Ltd.6$110
Theratechnologies Inc.3$92
Urgo Medical North America, LLC5$86
Takeda Pharmaceuticals U.S.A., Inc.5$85
Biohaven Pharmaceuticals, Inc.6$83
Kowa Pharmaceuticals America, Inc.5$74
Mimedx Group, Inc.2$67
Grifols USA, LLC4$66
Neurocrine Biosciences, Inc.3$62
W. L. Gore & Associates, Inc.3$48
Medtronic(2 entities)2$47
Exact Sciences3$46
Melinta Therapeutics, LLC3$38
Daiichi Sankyo Inc.2$36
Sanofi-aventis U.S. LLC2$34
Bard Peripheral Vascular, Inc.2$33
Ferring Pharmaceuticals Inc.2$29
Inspire Medical Systems, Inc.1$24
Corium, LLC1$23
Sanofi Pasteur Inc.1$22
Viiv Healthcare Company1$20
Bardy Diagnostics, Inc.1$20
Bsn Medical Inc1$19
Ossur Americas, Inc.1$18
Tetraphase Pharmaceuticals, Inc.1$18
Teva Pharmaceuticals USA, Inc.1$18
Corcept Therapeutics1$17
Shionogi Inc1$16
Bioventus LLC1$16
Otsuka America Pharmaceutical, Inc.1$15
Seqirus USA Inc1$15
Misonix Inc1$13
Integra Lifesciences Corporation1$13
Molnlycke Health Care US, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,829 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$350,229
Medicare patients
1,059
Services billed
20,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala64$276,056
StribildElviteg/Cob/Emtri/Tenofo Disop25$113,386
OzempicSemaglutide72$100,044
EliquisApixaban57$66,980
JardianceEmpagliflozin48$65,522
IsentressRaltegravir Potassium15$40,862
MounjaroTirzepatide22$37,994
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$37,660
JanuviaSitagliptin Phosphate37$35,118
MyrbetriqMirabegron31$30,853
Repatha SureclickEvolocumab34$30,234
XareltoRivaroxaban19$29,819
DescovyEmtricitabine/Tenofov Alafenam11$23,741
TrulicityDulaglutide15$19,966
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df55$14,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Stribild, Descovy$611$413,183100 claims
Novo NordiskOzempic$1,033$100,04472 claims
PfizerEliquis, Lyrica$535$76,71168 claims
MerckIsentress, Januvia$545$75,98052 claims
Boehringer IngelheimJardiance$318$65,52248 claims
Lilly USA, LLCMounjaro, Trulicity$548$57,96037 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$1,194$57,49996 claims
Johnson & JohnsonXarelto$673$29,81919 claims
BayerKerendia$502$12,79912 claims
AbbVieLinzess$950$9,98012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →